PROTAC BRD9 Degrader-7 is an orally active and selective degrader of BRD9 with a DC50 of 1.02 nM. PROTAC BRD9 Degrader-7 has superior oral activity with a Cmax of 3436.95 ng/mL.
References:
[1]. Jingyu Zhang, et al. Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia, European Journal of Medicinal Chemistry, Volume 262, 2023, 115872.
















